GenoMed In Discussions with Peru to Eliminate Most of Kidney Dialysis

FOR IMMEDIATE RELEASE

Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9938
dwmoskowitz@genomed.com

ST. LOUIS—January 26, 2009—GenoMed® (OTC Pink Sheets GMED.PK) announced today that its CEO, David Moskowitz MD, is meeting with the Director of the National Center for Kidney Health in Lima, Peru to discuss a program to prevent most kidney failure in Peru.

The Peruvian National Center for Kidney Health is the equivalent of the National Institute for Diabetes, Digestive, and Kidney Disease (NIDDK) in the U.S. A few years ago, it changed its name from the National Center for Dialysis, reflecting a new federal priority to prevent kidney failure.

GenoMed’s CEO, David Moskowitz MD, said, “Peru, like all of the Americas, has a very high incidence of diabetes. Like the United States, Peru has an epidemic of kidney failure. Unlike the US, though, Peru is serious about preventing kidney failure. As the only company in the world with a cure for 90% of kidney failure, we’re happy to be talking to the highest public health authority in Peru.”

Continued Dr. Moskowitz, “After years of trying to market to First World countries, we’ve recently turned our attention to the Third World. We’re finding much more interest in our products.”

Dr. Moskowitz concluded by saying, “Ironically, the developing world may profit first from advances in personalized medicine. Less infrastructure—fewer hospitals and dialysis units–actually turns out to be an advantage. There’s much less resistance to innovation. And the Internet allows us to deliver preventive molecular medicine inexpensively around the globe.”

About GenoMed

GenoMed published how to prevent 90% of kidney failure in 2002. It is now marketing its Next Generation Disease Management service globally to patients with diabetes or high blood pressure. Please contact GenoMed at www.genomed.com or www.thelatestmedicaltreatment.com.

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.